UroGen Pharma Q1 Revenue Hits $51M, ZUSDURI Sales Double, Secures $200M Loan
URGN has more than doubled off its 52-week low of $3.42.
Summary
UroGen Pharma reported Q1 2026 revenue of $51.0 million and a net loss of $23.6 million. A key highlight was the strong commercial performance of ZUSDURI, with net product revenue more than doubling quarter-over-quarter to $29.2 million. JELMYTO also contributed $21.7 million, up approximately 7% year-over-year. Additionally, the company secured a new $200 million loan agreement with Pharmakon Advisors, enhancing its financial flexibility. This report provides a positive update on product commercialization and liquidity, building on the revenue growth noted in the prior 10-K. Traders will focus on the continued sales momentum of ZUSDURI and pipeline advancements.
At the time of this announcement, URGN was trading at $23.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.42 to $30.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.